EcoR1 Capital, LLC - May 14, 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC
Stock symbol
ITOS
Transactions as of
May 14, 2025
Transactions value $
$38,685,562
Form type
4
Date filed
5/16/2025, 06:52 PM
Previous filing
May 13, 2025
Next filing
May 19, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
EcoR1 Capital, LLC 10%+ Owner 357 TEHAMA STREET #3, SAN FRANCISCO /s/ Oleg Nodelman, Manager of EcoR1 Capital, LLC 2025-05-16 0001587114

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Purchase $12.3M +1.66M +28.95% $7.41 7.39M May 14, 2025 See Note F1, F2, F3, F4
transaction ITOS Common Stock Purchase $26.4M +3.3M +44.66% $8.00 10.7M May 15, 2025 See Note F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2 Qualified Fund purchased 1,555,127 of the shares purchased in this transaction.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock.
F5 Qualified Fund purchased 3,093,422 of the shares purchased in this transaction.
F6 After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock.